论文部分内容阅读
目的分别采用以吡柔比星(THP)、表柔比星(EPI)为主的联合化疗方案用于乳腺癌新辅助化疗,进行疗效及不良反应观察比较。方法127例乳腺癌患者于手术前采用CTF方案治疗61例,采用CEF方案治疗66例。结果两组治疗有效率(CR+PR)分别为77%、71%,两组之间差异无显著性。不良反应:肝功能异常、白细胞减少、血小板减少、贫血、恶心呕吐、心肌损害,两组间比较差异无显著性。吡柔比星组脱发率低于表柔比星组,差异有显著性。结论吡柔比星、表柔比星对乳腺癌新辅助化疗的疗效无差异,THP组脱发轻于EPI组。
Objective To evaluate the efficacy and adverse reactions of combination chemotherapy with pirarubicin (THP) and epirubicin (EPI) in neoadjuvant chemotherapy of breast cancer. Methods A total of 127 breast cancer patients were treated with CTF regimen and 61 with CEF regimen. Results The effective rate of treatment (CR + PR) was 77% and 71% in both groups, with no significant difference between the two groups. Adverse reactions: liver dysfunction, leukopenia, thrombocytopenia, anemia, nausea, vomiting, myocardial damage, no significant difference between the two groups. Pirarubicin group hair loss rate was lower than the epirubicin group, the difference was significant. Conclusions Pirarubicin and epirubicin have no difference in the efficacy of neoadjuvant chemotherapy for breast cancer. The hair loss in THP group is less than that in EPI group.